



## RX.PA.015.CCH HYALURONIC ACID DERIVATIVES

The purpose of this policy is to define the prior authorization process for formulary hyaluronic acid products.

PREFERRED – PA REQUIRED	NON-PREFERRED – PA REQUIRED
<b>Single Injection</b>	
Synvisc-One (J7325)	Durolane (J7318)
	Gel-One (J7326)
	Monovisc (J7327)
<b>Multiple Injections</b>	
Euflexxa (J7323)	Gelsyn-3 (J7328)
Hyalgan (J7321)	Genvisc 850 (J7320)
Supartz (J7321)	Hymovis (J7322)
Visco-3 (J7321)	Orthovisc (J7324)
	Synvisc (J7325)
	Triluron (J7332)
	Trivisc (J7329)

Hyaluronic acid products improve elasticity and viscosity of synovial fluid. They are indicated to relieve pain associated with osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.

For reference purposes only:

- Durolane® course – 1 single injection
- Euflexxa® course – 3 injections 1 week apart
- Gel-One® course – 1 single injection
- Gelsyn-3® course – 3 injections 1 week apart
- Genvisc 850® course – 3 to 5 injections 1 week apart
- Hyalgan® course – 3 to 5 injections 1 week apart
- Hymovis® course – 2 injections 1 week apart
- Monovisc® course – 1 single injection
- Orthovisc® course – 3 to 4 injections 1 week apart
- Supartz® course – 3 to 5 injections 1 week apart
- Synvisc® course – 3 injections 1 week apart

### ***Hyaluronic Acid Products***

**POLICY NUMBER: RX.PA.015.CCH**

**REVISION DATE: 3/22**

**PAGE NUMBER: 2 of 4**

- Synvisc-One® course – 1 single injection
- Trilon® course – 3 injections 1 week apart
- Trivisc® course – 3 injections 1 week apart
- Visco-3® course – 3 injections 1 week apart

### **POLICY**

It is the policy of the Health Plan to maintain a prior authorization process that promotes appropriate utilization of specific drugs with potential for misuse or limited indications. This process involves a review using Food and Drug Administration (FDA) criteria to make a determination of Medical Necessity and approval by the Medical Policy Committee.

The hyaluronic acid products are subject to the prior authorization process.

### **PROCEDURE**

#### **Initial Authorization Criteria:**

*Must meet all the criteria listed under the respective diagnosis:*

#### **For All Products:**

- Must have a diagnosis of mild-to-moderate osteoarthritis or degenerative joint disease of the knee
- Must have documentation of a previous trial and failure (at least 3 months), contraindication, or intolerance to simple analgesics (such as acetaminophen-containing products)
- Must have documentation of a previous trial and failure (at least 3 months), contraindication, or intolerance to prescription strength non-steroidal anti-inflammatory drugs (NSAIDs)
- Must have documentation of a trial of steroid injections within the past 2 months and aspiration for effusion without success, or have a documented medical reason to not utilize steroid injections
- Must have documentation of a trial and failure of physician-directed exercise or a physical therapy program
- **For non-preferred products:**
  - Must have documentation of a previous trial and failure, contraindication, or intolerance to the preferred product(s) (single or multiple injection)

#### **Reauthorization Criteria:**

All prior authorization renewals are reviewed to determine the Medical Necessity for continuation of therapy. Authorization may be extended based upon chart documentation of significant improvement in pain and functional capacity.

**Limitations:**

<b>Length of Authorization (if above criteria met)</b>	
Initial Authorization	Up to 12 months <ul style="list-style-type: none"> <li>• 2 yearly injection courses for each knee per 6 months</li> <li>• 2 fills per year for the treatment of 1 knee and 4 fills per year for treatment of both knees</li> </ul>
Reauthorization	Case-by-case basis

If the established criteria are not met, the request is referred to a Medical Director for review, if required for the plan and level of request.

**HCPCS Codes:**

CPT Code	Brand	Description
J7318	DUROLANE	HYALURONAN OR DERIVATIVE, DUROLANE, FOR INTRA-ARTICULAR INJECTION, 1 MG
J7320	GENVISC 850	HYALURONAN OR DERIVATIVE, GENVISC 850, FOR INTRA-ARTICULAR INJECTION, 1 MG
J7321	HYALGAN, SUPARTZ, VISCO-3	HYALURONAN OR DERIVATIVE HYALGAN, SUPARTZ OR VISCO-3, FOR INTRA-ARTICULAR INJECTION, PER DOSE
J7322	HYMOVIS	HYALURONAN OR DERIVATIVE, HYMOVIS, FOR INTRA-ARTICULAR INJECTION, 1 MG
J7323	EUFLEXXA	HYALURONAN OR DERIVATIVE, EUFLEXXA, FOR INTRA-ARTICULAR INJECTION, PER DOSE
J7324	ORTHOVISC	HYALURONAN OR DERIVATIVE, ORTHOVISC, FOR INTRA-ARTICULAR INJECTION, PER DOSE
J7325	SYNVISC, SYNVISC-ONE	HYALURONAN OR DERIVATIVE, SYNVISC OR SYNVISC-ONE, FOR INTRA-ARTICULAR INJECTION, 1 MG
J7326	GEL-ONE	HYALURONAN OR DERIVATIVE, GEL-ONE, FOR INTRA-ARTICULAR INJECTION, PER DOSE
J7327	MONOVISC	HYALURONAN OR DERIVATIVE, MONOVISC, FOR INTRA-ARTICULAR INJECTION, PER DOSE
J7328	GELSYN-3	HYALURONAN OR DERIVATIVE, GELSYN-3, FOR INTRA-ARTICULAR INJECTION, 0.1 MG
J7329	TRIVISC	HYALURONAN OR DERIVATIVE, TRIVISC, FOR INTRA-ARTICULAR INJECTION, 1 MG
J7332	TRILURON	HYALURONAN OR DERIVATIVE, TRILURON, FOR INTRA-ARTICULAR INJECTION, 1 MG

**REFERENCES**

1. Orthovisc [package insert]. Woburn, MA: Anika Therapeutics, Inc.; June 2005.
2. Euflexxa [package insert]. Suffern, NY: Ferring Pharmaceuticals, Inc.; May 2006.
3. Synvisc [package insert]. Madison, NJ: Wyeth Pharmaceuticals, Inc.; December 2006.
4. Supartz [package insert]. Largo, FL: Smith & Nephew, Inc.; January 2006.
5. Hyalgan [package insert]. New York, NY: Sanofi-Synthelabo, Inc.; January 2005.
6. American College of Rheumatology. Arthritis & Rheumatism 2000; 43: 1905-1915. Accessed July 24, 2007. URL: <http://www.rheumatology.org/publications/guidelines/oa-mgmt/oa-mgmt.asp>.
7. Gel-One [package insert]. Warsaw, IN: Zimmer, Inc; May 2011.

**RECORD RETENTION**

Records Retention for Evolent Health documents, regardless of medium, are provided within the Evolent Health records retention policy and as indicated in CORP.028.E Records Retention Policy and Procedure.

**REVIEW HISTORY**

DESCRIPTION OF REVIEW / REVISION	DATE APPROVED
Initial Review	3/22